Agwuegbo Chibuike Charles, Antia Akanimo Usen, Shamaki Garba Rimamskep, Bob-Manuel Tamunoinemi
Department of Medicine, Southwest Healthcare, Temecula, California.
Department of Medicine, Lincoln Medical Center, Bronx.
Curr Opin Cardiol. 2024 Jul 1;39(4):244-250. doi: 10.1097/HCO.0000000000001146. Epub 2024 Apr 3.
This review article discusses the controversies, strengths, and limitations of the current literature on renal artery denervation in the management of resistant hypertension, as well as the future directions of this intervention.
There have been conflicting data from the different randomized control trials assessing the efficacy of renal artery denervation in the management of resistant hypertension.
Renal artery denervation is achieved by ablating the sympathetic nerves surrounding the renal arteries using endovascular ultrasound, radiofrequency, or alcohol. Our review article highlights that renal artery denervation is generally effective in improving blood pressure in patients with resistant hypertension. The Food and Drug Administration (FDA) has recently approved the ReCor Medical Paradise system, and the Symplicity Spyral RDN systems for renal artery denervation.
本文综述探讨了当前关于肾动脉去神经支配术治疗顽固性高血压的文献中的争议、优势和局限性，以及该干预措施的未来方向。
不同的随机对照试验评估肾动脉去神经支配术治疗顽固性高血压疗效的数据相互矛盾。
肾动脉去神经支配术是通过血管内超声、射频或酒精消融肾动脉周围的交感神经来实现的。我们的综述文章强调，肾动脉去神经支配术通常对改善顽固性高血压患者的血压有效。美国食品药品监督管理局（FDA）最近已批准ReCor Medical Paradise系统和Symplicity Spyral RDN系统用于肾动脉去神经支配术。
